Page last updated: 2024-12-05

pipenzolate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pipenzolate is a synthetic anticholinergic drug that acts as a muscarinic antagonist. It was initially developed for the treatment of gastrointestinal disorders, such as peptic ulcers, irritable bowel syndrome, and diarrhea. Pipenzolate works by blocking the action of acetylcholine at muscarinic receptors, which are found in the smooth muscles of the gastrointestinal tract. This results in decreased muscle contractions and reduced motility. Research on pipenzolate has focused on its pharmacological properties, mechanisms of action, and therapeutic potential. However, its use has been limited due to potential side effects, such as dry mouth, blurred vision, and urinary retention. Further studies are needed to investigate the safety and efficacy of pipenzolate for specific medical conditions. It is also of interest in the study of the effects of anticholinergics on the nervous system.'

pipenzolate: RN given refers to parent cpd; NM refers to bromide; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4832
CHEMBL ID1619528
CHEBI ID95178
MeSH IDM0045434

Synonyms (54)

Synonym
KBIO1_000638
DIVK1C_000638
SPECTRUM_001304
SPECTRUM5_001065
BSPBIO_002992
IDI1_000638
PRESTWICK2_000760
BPBIO1_000858
piperidinium, 1-ethyl-3-((hydroxydiphenylacetyl)oxyl)-1-methyl-
brn 1506094
piperidinium, 1-ethyl-3-hydroxy-1-methyl-, benzilate (ester)
pipenzolate
einecs 236-748-1
1-ethyl-1-methyl-3-(oxidodiphenylacetoxy)piperidinium
pipenzolonum
1-ethyl-3-hydroxy-1-methylpiperidinium bromide benzilate
AB00053816
BSPBIO_000780
KBIO2_006920
KBIO3_002492
KBIOGR_001108
KBIO2_001784
KBIO2_004352
KBIOSS_001784
PRESTWICK0_000760
PRESTWICK1_000760
SPBIO_001587
SPECTRUM2_001514
SPBIO_002719
SPECTRUM3_001546
NINDS_000638
SPECTRUM4_000754
PRESTWICK3_000760
(1-ethyl-1-methylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
NCGC00018203-02
unii-rs3k5yxv34
13473-38-6
5-21-01-00043 (beilstein handbook reference)
rs3k5yxv34 ,
pipenzolate [who-dd]
1-ethyl-3-hydroxy-1-methylpiperidinium benzilate
CHEMBL1619528
pipenzolate cation
pipenzolate ion
DTXSID9048481
HY-B0953
AB00053816_15
AB00053816_16
CHEBI:95178
2-hydroxy-2,2-diphenylacetic acid (1-ethyl-1-methyl-3-piperidin-1-iumyl) ester
SBI-0051757.P002
DB13844
Q2096435
BRD-A53561827-004-15-7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (77.78)18.7374
1990's1 (11.11)18.2507
2000's0 (0.00)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.50 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]